Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

Special Report

NeurologyLive Peer Exchange

Medcast

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Expert Authors

FDA News

Features

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Job Board

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

The FDA expands Vizamyl's use for Alzheimer diagnosis and therapy monitoring, enhancing patient care with precise amyloid quantification.

FDA Greenlights Expanded Indication for Vizamyl in Alzheimer Disease Diagnosis

Skyhawk Therapeutics initiates FALCON-HD trial for SKY-0515, a promising treatment for Huntington disease, aiming to modify disease progression.

Patient Dosing Underway in Phase 2/3 FALCON-HD Trial of SKY-0515 for Huntington Disease

Videos

The postdoctoral researcher at the Woolcock Institute of Medical Research highlighted EEG-based evidence supporting ALKS 2680's wake-promoting effects in patients with narcolepsy and idiopathic hypersomnia. [WATCH TIME: 3 minutes]

Understanding ALKS 2680’s Wake-Promoting Effects Through qEEG: Julia Chapman, PhD

Fremanezumab shows significant long-term effectiveness in reducing migraine frequency and severity, enhancing patient outcomes in chronic and episodic cases.

Phase 4 PEARL Study Confirms Long-Term Effectiveness of Fremanezumab in Preventing Chronic, Episodic Migraine

Associate professor of neurology at Emory University and co-director of the Emory ALS Center.

Experts in ALS care and research shared their optimism about emerging treatments, aiming to deepen scientific understanding, and the potential role of advocacy in accelerating progress. [WATCH TIME: 4 minutes]

Clinicians Express Growing Optimism in ALS Research and Treatment Advancements

Chief Scientific Officer, Dravet Syndrome Foundation

Veronica Hood, PhD, chief scientific officer at the Dravet Syndrome Foundation, discussed the evolving care landscape of Dravet syndrome, highlighting breakthroughs in precision medicine and promising new therapies for patients.

The Changing Landscape of Dravet Syndrome 

Experts discussed the ongoing importance of awareness, funding, and early diagnosis in amyotrophic lateral sclerosis, welcoming the return of the well-known Ice Bucket Challenge. [WATCH TIME: 5 minutes]

Reviving ALS Awareness Campaigns to Reaffirm Support for the Patient Community

Clinicians reflected on the unique, patient-centered format of the ALS Nexus conference and its potential role in accelerating ALS research and promoting care collaboration. [WATCH TIME: 4 minutes]

Highlighting the Collaborative and Inclusive Spirit of the ALS Nexus Conference

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

LinkedIN

YouTube

Spotlight

CMSC 2025

PNS 2025

SLEEP 2025

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

News Network

1rem

View

Treatment and Management of Mild-to-Moderate Multiple Sclerosis

Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

How do you choose between different therapies for moderate MS in the context of other conditions?

Patients with comorbidities (eg, cardiovascular diseases, risk of infection, liver damage, cancer)

Patients considering pregnancy in the near future

Patients who have late onset MS or are older

In a panel discussion, multiple sclerosis (MS) experts Stephen Krieger, MD; Heidi Crayton, MD; Jacqueline Nicholas, MD, PhD; Patricia Coyle, MD, and Enrique Alvarez, MD, PhD, share their insights on current MS therapies, aspirations for guideline revisions, the importance of shared decision-making, and the role of medium-efficacy therapy in the management of mild-to-moderate MS.

Key opinion leaders provide insights into the prevalence and incidence of clinically isolated syndrome (CIS) within their clinical practice.

Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

The panelists explore diagnostic methods for differentiating between mild and moderate multiple sclerosis (MS) while also examining prognostic factors, the role of imaging, and the concept of brain reserve in mild MS cases.

Defining Mild Multiple Sclerosis

Multiple sclerosis (MS) specialists discuss their observations regarding variations in MS presentation and progression among patients of Different Races and Ethnicities

Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

The expert panel examines early multiple sclerosis (MS) and patients with mild MS even in later stages of the disease, emphasizing crucial information to convey to patients throughout their journey; faculty also explore cases where disease-modifying therapies (DMTs) may not be utilized.

Conversations With Patients About Mild/Moderate Multiple Sclerosis

The key opinion leaders provide recommendations on the optimal frequency for evaluating disease progression in patients with mild to moderate MS, emphasizing effective monitoring methods and the most appropriate tools for best clinical practice.

Monitoring Patients With Mild/Moderate Multiple Sclerosis

The panel reflects on their experiences as practicing clinicians, emphasizing the significance of shared decision-making and actively listening to patients’ preferences regarding management of their MS. 

Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

Multiple sclerosis (MS) treatment specialists discuss the challenges associated with the early use of high-efficacy therapy (HET) in patients with mild to moderate MS and delve into the broader debate surrounding the consistent use of HET for managing mild to moderate MS cases.

De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

Key opinion leaders share their approach to treatment sequencing for patients with multiple sclerosis (MS), taking into account comorbidities such as cardiovascular diseases, risk of infection, liver damage, and cancer as well as considering factors like planned pregnancy or advanced age.

The panel explores factors influencing treatment adherence in multiple sclerosis (MS) patients and highlights the importance of shared decision-making in promoting and maintaining patient adherence to their prescribed therapy.

Treatment Adherence in Mild Multiple Sclerosis

Medical experts debate the concept of benign multiple sclerosis (MS), questioning whether this subtype truly exists or if it is a misnomer in the context of the disease's long-term progression and impact on patients.

Benign Multiple Sclerosis

The panel identifies and discusses the unmet needs of patients with mild to moderate multiple sclerosis (MS), highlighting areas where current treatment options and management strategies fall short in addressing the unique challenges faced by this patient population.

Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

Key opinion leaders explore the impact of newly available biosimilars and generic biologics for managing multiple sclerosis (MS), discussing how these developments have altered patient access to treatments and the implications for the future of the MS treatment landscape.

Generics and Biosimilars in Multiple Sclerosis

Key opinion leaders examine the available data on Bruton tyrosine kinase (BTK) inhibitors to assess whether the evidence supports their efficacy as a treatment option for multiple sclerosis (MS).

Emerging Treatments in Mild/Moderate Multiple Sclerosis

In closing, the panel of experts in multiple sclerosis (MS) offer their insights and recommendations for clinicians, emphasizing best practices to optimize patient care and improve overall outcomes in the management of MS.

Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

Peer Exchange

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP: 1.Presentation of Clinically Isolated Syndrome/First Attack of Multiple Sclerosis

EP: 2.Defining Mild Multiple Sclerosis

EP: 3.Mild/Moderate Multiple Sclerosis in Patients of Different Races and Ethnicities

EP: 4.Conversations With Patients About Mild/Moderate Multiple Sclerosis

EP: 5.Monitoring Patients With Mild/Moderate Multiple Sclerosis

EP: 6.Shared Decision-Making for Patients With Mild/Moderate Multiple sclerosis

EP: 7.De-Escalation Strategies and Challenges With the Use of HET in Mild/Moderate Multiple Sclerosis

EP: 8.Choosing Between Moderate Therapies for Mild/Moderate Multiple Sclerosis

EP: 9.Treatment Adherence in Mild Multiple Sclerosis

EP: 10.Benign Multiple Sclerosis

EP: 11.Diagnostic Uncertainty, Monitoring and Other Unmet Needs in Mild/Moderate Multiple Sclerosis

EP: 12.Generics and Biosimilars in Multiple Sclerosis

EP: 13.Emerging Treatments in Mild/Moderate Multiple Sclerosis

EP: 14.Final Thoughts on Caring for Patients With Mild/Moderate Multiple Sclerosis

Newsletter